FibroGen (NASDAQ:FGEN) CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $53.14, for a total transaction of $2,106,257.04. Following the completion of the sale, the chief executive officer now directly owns 2,907,425 shares of the company’s stock, valued at $154,500,564.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
NASDAQ FGEN traded down $1.20 during trading hours on Monday, reaching $45.00. The company had a trading volume of 607,252 shares, compared to its average volume of 615,564. The stock has a market capitalization of $3,819.21, a P/E ratio of -26.01 and a beta of 1.89. FibroGen has a 1-year low of $22.75 and a 1-year high of $63.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.70 and a quick ratio of 9.70.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. The firm had revenue of $42.51 million for the quarter, compared to analysts’ expectations of $45.37 million. FibroGen had a negative net margin of 100.43% and a negative return on equity of 32.08%. analysts anticipate that FibroGen will post -1.35 EPS for the current year.
Several equities research analysts have recently issued reports on the stock. Mizuho restated a “hold” rating and issued a $61.00 target price on shares of FibroGen in a report on Thursday. Zacks Investment Research downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. ValuEngine downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. TheStreet upgraded shares of FibroGen from a “d” rating to a “c-” rating in a research note on Tuesday, February 27th. Finally, Leerink Swann restated an “outperform” rating and set a $88.00 price objective (up from $80.00) on shares of FibroGen in a research note on Wednesday, February 28th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $66.67.
WARNING: This piece was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://baseballnewssource.com/2018/04/02/fibrogen-inc-fgen-ceo-thomas-b-neff-sells-39636-shares/2007340.html.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.